Verona Pharma PLC - רווח למניה לשנה מתגלגלת VRNA

Verona Pharma plc (VRNA) focuses on launching a unique combined-action COPD treatment in the US market. This chart of YoY TTM earnings per share growth reflects the current resilience of the business, with the metric fixed at 50.20. Digital trial monitoring accelerates analytics, while commercialization success in the respiratory niche depends directly on FDA approval and physician loyalty.
Verona Pharma PLC - פילוחים אנליטיים ומדדי מפתח (VRNA)

Year-over-year EPS growth (TTM) reflects the rate of change in net income per share over a twelve-month period. By analyzing the annual percentage change in TTM EPS, an investor captures the scaling speed of real return on equity. This metric is calculated as the ratio of current earnings to the previous year's value, revealing operational efficiency. For Verona Pharma plc (VRNA), this indicator confirms the commercial success of implementing new respiratory therapy standards.